Captivision Teams Up with Activision's Call of Duty®:
MIAMI and SEOUL, April 24, 2024 (GLOBE NEWSWIRE) -- Captivision Inc. (NASDAQ: CAPT), a pioneer and manufacturer of architectural media glass, today...
Stay updated with breaking news from Registration Statement Form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MIAMI and SEOUL, April 24, 2024 (GLOBE NEWSWIRE) -- Captivision Inc. (NASDAQ: CAPT), a pioneer and manufacturer of architectural media glass, today...
ZOOZ Power Ltd. Ordinary Shares and Public Warrants to Trade on Nasdaq under the Symbols “ZOOZ” and “ZOOZW,” respectively NEW YORK, NY, April 04, 2024 -- Keyarch Acquisition...
SEOUL, South Korea, March 25, 2024 (GLOBE NEWSWIRE) -- Captivision Inc. (NASDAQ: CAPT) today announced that Gary R. Garrabrant has been appointe...
NEEDHAM, Mass., Feb. 28, 2024 /PRNewswire/ -- NB Bancorp, Inc. , the holding company of Needham Bank, today announced its 2023 financial results. Concurrent with its mutual-to-stock conversion and...
Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program